Study Type: POEM Purpose: Whereas statins are efficacious in patients with type 2 diabetes and rates of CV events remain high, the ACCORD-lipid trial compared statin alone versus statin with a fibrate for reduction in the CV events. Fibrates were chosen to raise HDL and lower TG. Study Duration: 5 year mean follow-up; n = 5,518 (of the 10,251 in total ACCORD study group) Trial Design: randomized, double-blinded, intention-to-treat, multicenter (77 centers in US and Canada) Treatment Groups: Simvastatin (dose to guideline) started in all patients at randomization visit, fenofibrate 160 mg daily or placebo was added 1 month later. The dose of fenofibrate was renally dosed. Patients: 5,518 patients in total, mean of 10 year history of DM, mean age 62 years, 68% white, 15% black, 30% female, 60% some college or finished college, 95 kg, BMI = 32, BP mean 134/74, HbA1c = 8.3%, FBG = 176, LDL = 100, HDL 38, TG 162, 37% with previous CV event, 5% with HF, 2% with amputation, 15% smokers (39% never smoked), K = 4.5, SCr = 0.9 (GFR 92) Medication history: Insulin (33%), Metformin (62%), sulfonylurea (52%), TZD (18%), ASA (56%), ACEI (54%), ARB (15%), beta-blocker (33%), thiazide (26%), statin (60%), Any lipid therapy (65%) Inclusion: Type 2 patients with HbA1c 7.5% or more, ages 40 to 79 with CV disease, ages 55 to 79 with anatomical evidence of CV disease, albuminuria, LVH or with risk factors. Added inclusion for lipid arm: LDL 60-180; HDL < 55 for female and blacks or < 50 for all other groups; TG < 750 if not on lipid therapy or < 400 if on lipid therapy Exclusion: frequent hypoglycemia, BMI > 45, SCr > 1.5, serious illness Outcome Events: Primary endpoints: First occurrence of nonfatal MI or nonfatal stroke or death from CV causes Secondary causes: see table
1.
Are 
Conclusion:
The addition of fenofibrate to increase HDL and reduce TG in patients with type 2 diabetes who were already on simvastatin, did not result in additional cardiovascular benefit.
